Displaying 1 - 20 of 1703
FTC and DOJ Issue Fiscal Year 2025 Hart-Scott-Rodino Annual Report
FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal
Aurobindo-Lannett, In the Matter of
The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.
FTC Approves Final Consent Order in Micromarket Kiosks Deal
FTC Finalizes Consent Order in Sevita, BrightSpring Acquisition
Centerbridge Seaport Acquisition Fund/BrightSpring Health Services, Inc.
The Federal Trade Commission took action to protect Americans with intellectual and developmental disabilities and their families by requiring Sevita Health (Sevita) to divest more than 100 healthcare facilities to resolve antitrust concerns surrounding its proposed $835 million acquisition of BrightSpring Health Services, Inc.’s (BrightSpring) community living business.
Under the FTC’s proposed consent order, Sevita will be required to divest 128 intermediate care facilities (ICFs), which provide IDD services, and other assets such as day-training programs. The divested facilities—which are in Indiana, Louisiana, and Texas—will be acquired by Dungarvin Group, Inc. (Dungarvin), an experienced and well-regarded operator of ICFs.
On June 10, 2026, the FTC finalized the consent order in this matter.
FTC Requires Divestiture of Ambulatory Surgery Centers to Protect Patients from Anticompetitive Effects of Ascension Health-AmSurg Deal
Ascension/AMSURG, In the Matter of
The Federal Trade Commission took action to protect American patients from higher outpatient surgery costs by requiring national nonprofit health system Ascension Health Alliance (Ascension) to divest several surgery center facilities to complete its proposed $3.9 billion acquisition of AmSurg LLC.